ENP Newswire -
Release date- 15072014 -
Operational results increased 9.4% and the negative impact of currency was 0.3%. Domestic sales increased 14.9%. International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.
Net earnings and diluted earnings per share for the second quarter of 2014 were
'Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities,' said
The Company increased its earnings guidance for full-year 2014 to
Worldwide Consumer sales of
Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.
Positive contributors to operational results were sales of TYLENOL and MOTRIN analgesics; over-the-counter upper respiratory medicines as well as anti-smoking aids;
Worldwide Pharmaceutical sales of
The strong sales results were primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA (ibrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in patients who have had at least one prior therapy.
Additional contributors to operational sales growth were STELARA (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; REMICADE (infliximab) and SIMPONI/SIMPONI ARIA (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; and PREZISTA (darunavir), a treatment for HIV.
Sales results were negatively impacted by loss of exclusivity for ACIPHEX (rabeprazole), a proton pump inhibitor for gastrointestinal disorders, and CONCERTA (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.
During the quarter, the
In addition, a supplemental New Drug Application (sNDA) was submitted to the
A Marketing Authorization Application was submitted to the
Worldwide Medical Devices and Diagnostics sales of
Primary contributors to operational growth were hip and trauma products in the Orthopaedics business,
Sales results in the U.S. Diabetes Care business were negatively impacted by price declines associated with the implementation of
During the quarter, the SABER PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease received
Subsequent to the quarter, on
Most Popular Stories
- Islamic State Obliterating Cultural Landmarks in Mosul
- The 2014 Fastest-Growing 100
- 'Lucy's' Super Powers Tops 'Hercules' at Box Office
- VW Site Could Mean Another 2,000 Jobs for Chattanooga
- RV Sales See Highest Increase Post Great Recession
- Report: China to Declare Qualcomm a Monopoly
- Eid al-Fitr Celebrations Mark End of Ramadan
- Oppression of Women Cripples Africa: Obama
- Insecticides Permeate U.S. Food, Water Supply
- Anarchy, Chaos Sweep Across Libya